Add to Basket
Order hotline:
![]() |
+1 404 474 4654 |
![]() |
+1 888 205 9894 (TF) |
Amyloid beta (Abeta) (N-Term) antibody
| Antigen | Amyloid beta (Abeta) |
| Synonyms | AAA, AD1, PN2, ABPP, APPI, CVAP, ABETA, CTFgamma, aaa, ad1, pn2, abpp, appi, cvap, abeta, MGC88882, ctfgamma, APP |
| Epitope |
Alternatives N-Term |
| Clonality | Monoclonal (8-20E-02) |
| Host |
Alternatives Mouse |
| Reactivity |
Alternatives Human |
| Application |
Alternatives Immunohistochemistry (IHC), Western Blotting (WB)
|
![]() |
1 reference available |
| Catalog no. | ABIN180060 |
| Quantity | 50 µg |
| Price | 517.00 $ Plus shipping costs $35.00 |
| Shipping to |
|
| Availability | Ships within 10 to 15 Business Days |
Additional Information
| Alternative name | Amyloid beta (N) (82E1) |
| Immunogen | Synthetic peptide for Human Amyloid (1-16) (DAEFRHDSGYEVHHQK) |
| Isotype | IgG1 (Matching secondary antibodies) |
| Clone | 8-20E-02 |
| Description | Alzheimer's disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major protein component of these plaques is beta amyloid peptide (A), a 40 to 43 amino acid peptide cleaved from amyloid precursor protein by beta-secretase and a putative secretase. Increased release of the `longer forms' of A peptide, A42 or A43, which have a greater tendency to aggregate than A40, occurs in individuals expressing certain genetic mutations, expressing certain ApoE alles, or may involve other, still undiscovered, factors, Many researchers theorize that it is this increased release of A42/A 43 which leads to the abnormal deposition of A and the associated neurotoxicity in the brains of affected individuals. This antibody specifically reacts human A N-terminal end, therefore it is very useful to detect APP fragments generated by -secretase cleavage. |
| Specificity | Human Amyloid N-terminal specific. Reacts with both soluble and fibrillar A to a similar degree. Nonreactive with non-cleaved APP. No crossreactivities with mouse and rat. |
Application Details
| Application Notes | This antibody can be stained in formalin fixed paraffin embedded tissues after formic acid treatment*1 by several Immunohistochemical techniques such as Avidin Biotin Complex (ABC) Method. The optimal dilution is about 1µg /ml, however, the dilution rate should be optimized by each laboratories. *1: rinsing by running water after formic acid treatment for 5 minutes following de-paraffin. |
| Purification | Antigen peptide |
| Buffer | Lyophilized product from 1% BSA in PBS containing 0.05% NaN3 Reconstitution: 0.5mL distilled water will be added to the product (The conc. comes up 100 µg/mL) |
| Storage | Lyophilized product, 5 years at 2 8 |
| Research Area | Alzheimer's Disease |
| Restrictions | For Research Use only |
Publications
| Publications |
Ikeuchi, Kaneko, Miyashita et al.: "Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations." in: Dementia and geriatric cognitive disorders, Vol. 26, Issue 1, pp. 43-9, 2008 (PubMed).
|
Alternatives
Alternatives for antigen "Amyloid beta (Abeta)", type "Antibodies"




Alternatives